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Weekly cabazitaxel in “unfit” metastatic castration resistant prostate
cancer patients (mCRPC) progressing after docetaxel (D) treatment.
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Background: Cabazitaxel (C), a novel taxane developed to overcome D
resistance, showed an overall survival improvement after D in mCRPC in
a three-weekly schedule. Its main toxicity is hematological, especially in
unfit patients (Pts). We aimed to evaluate efficacy and safety of weekly
C/prednisone (P) schedule in “unfit” mCRPC previously treated with D.
Possible relation of CTC counts and its early response with efficacy is
analyzed.
Methods: Pts with mCRPC progressing after D treatment with adequate
bone marrow, liver and kidney functions were included in this open-label
non-comparative trial. Unfit pts defined as ECOG 2, dose reduction due to
febrile neutropenia during D treatment or radiation therapy affecting more
than 25% of bone marrow reserve. C 10mg/m2 was administered on days
1, 8, 15 and 22 of 5-week cycles with P (5mg b.i.d.). Radiological and
PSA response were evaluated according to the PCWG2 criteria and toxicity
according NCI-CTC AE.
Results: 70 pts have been enrolled and 1 of them is still on treatment.
Median age was 73 y (range 54−85), 71% pts had ECOG 2, 81% had
bone, 16% liver and 11% lung metastases. Treatment: 302 cycles (median:
3; range: 1−14); 1116 weekly infusions (median 11; range 1−54). Median
dose intensity was 89%. Twenty-two of 59 pts (37.3%) achieve 50%
PSA response and 7 (11.9%) 80% PSA response. Radiological response
was evaluable in 62 pts. PR was observed in 4 pt (6.5%) and SD
in 33 pts (53.2%). Median PSA PFS was 6.7 months and 12 weeks
PSA PFS was 78.7%. Median OS was 12.6 months. Most frequent
toxicities of all grades and grade 3−4 as % of pts were: anemia (68.6–
15.7%), asthenia (60.0–15.7%), thrombocytopenia (15.7−8.6%), diarrhea
(35.7−1.4%), nauseas (27.1−1.4%), neutropenia (12.9−4.3%), peripheral
neuropathy (8.6−0.0%), and anorexia (25.7−2.9%). Neither grade IV
diarrhea nor febrile neutropenia were observed.
Sixteen pts had basal CTC <5 cells/7.5mL (A) and 40 5 cells/7.5mL (B).
Ten pts had early CTC response (conversion from B to A at 4 weeks),
1 CTC progression and 29 did not change CTC group. Results show a
favorable association between basal CTC and PFS (median 10.5 (A) vs 4.6
(B) months; p = 0.035). Association between basal CTC and OS (median
14.6 (A) vs 10.9 (B) months; p = 0.088) and CTC early response and OS
(median 17.9 (responders) vs 12.7 months (non-responders); p = 0.190)
did not reached statistical significance.
Conclusions: Weekly cabazitaxel plus P administered to unfit pts seems
as effective as 3-weekly standard treatment but with much lesser toxicity.
Basal CTC seems to be related with PFS and OS.
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Background: Abiraterone acetate (AA) is a potent, selective androgen
(CYP17) biosynthesis inhibitor, which showed to improve overall survival
(HR = 0.646) in mCRPC patients progressing after docetaxel. In this
retrospective analysis we assessed the safety and efficacy of AA in
patients affected with mCRPC progressing after chemotherapy, treated in
the normal clinical practice, in several Italian Oncologic Units, after the
approval of the drug from the Italian Drug Agency (AIFA).
Material and Methods: We retrospectively reviewed the clinical data
of patients affected with mCRCP progressive after chemotherapy who
received AA (1000mg/d) plus prednisone (5mg/twice daily). Pts were
considered eligible if they had received docetaxel as prior chemotherapy.
A total of 189 patients were included in the analysis. Main patient
characteristics were: median age: 70 years (range 44−89), Gleason
score >7: 84%; median PSA at AA start: 35 (range 0.36–2100); duration of
prior hormonal therapy <12 vs 12 months: 38 vs 62%; no. of metastatic
sites: 1 vs 2: 73 vs 27%; bone only 48%, presence of visceral disease
51%; symptomatic vs non-symptomatic: 53 vs 47%; median number of prior
docetaxel courses: 6 (range 1−15); second-line cabazitaxel: 14%. Forty-
four percent of patients received bisphosphonates during AA treatment.
Results: AA was well tolerated and no relevant toxicity were observed.
After a median follow-up of 8.5 months (range 1−51) the median
progression-free survival (PFS) and the median overall survival (OS) were
10 months (95%CI: 7−13) and 26 months (95%CI: 17−35) respectively.
No differences in PFS and OS were found based on the response to
docetaxel. Patients who received hormonal treatment for 12 months had
a statistically significant longer PFS (13 vs 7 months, p = 0.009) and OS
(28 vs 17 months, p = 0.03 months). The median decrease in the PSA level
>50% was observed in 36% of patients. Patients with only bone metastasis
had a PFS of 13 (95%CI: 7.18) and OS 28 months (95%CI:16−40). Twelve
patients (6%) presented a scheletal-related event (SRE).
Conclusions: The results achieved in this analysis although retrospective,
confirms the activity and safety of AA in these subset of patients.
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Background: In the COU-AA-301 trial, abiraterone acetate plus low dose
prednisone (AA) was found to extend survival in metastatic castrate
resistant prostate cancer (mCRPC) patients progressing after docetaxel
chemotherapy compared to placebo plus low dose prednisone. However,
limited data related to AA treatment and outcomes is available in the
real-world. The primary objective of this study was to evaluate treatment
duration associated with AA treatment in routine clinical practice in mCRPC
patients in the post-chemotherapy setting across four European countries:
Belgium, France, Germany and the Netherlands. Other clinical data such
as treatment sequencing and survival were assessed to place the treatment
duration into context.
Material and Methods: The study was designed as a retrospective chart
review. Patients were identified through treating oncologists and urologists
registered in the IMS Health Medical Radar physician database. Eligible
mCRPC patients were aged 18 years at AA initiation (i.e. baseline),
previously treated with docetaxel and naı¨ve to prior AA treatment. Baseline
patient characteristics were described using summary statistics. Kaplan–
